Purchase this article with an account.
Wendel Martins, Marcelo Hatanaka, Luciana M Alencar, Wilma Lelis, Ricardo Suzuki, Isabella Landin, Maiara Moraes, Remo Susanna; Water-drinking test for monocular trial with prostaglandin analogue in patients with primary open angle glaucoma or ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2014;55(13):126.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the reproducibility of the modified diurnal tension curve (mDTC) and the water-drinking test (WDT) in patients with primary open angle glaucoma or ocular hypertension submitted to monocular trial with prostaglandin analogue.
Nineteen subjects were submitted to mDTC followed by WDT in both eyes, under no treatment. Treatment with prostaglandin analogues was initiated on the same night in only one randomized eye per patient. The mDTC and WDT were repeated on the following day and after one week on the monocular trial. Intraclass correlation coefficients (ICC) were used to determine the reproducibility of mean intraocular pressure (IOP) during the mDTC and peak IOP on the WDT, and to compare treated eyes with their contralateral non-treated eyes
In untreated eyes reproducibility of mean IOP was good, but higher between the two first days than after one week, with ICCs for mean mDTC IOP was 0,83 between the first two days, and 0,79 between the first test and one week later. The IOP peaks for the WDT had excellent reproducibility between the first two days (ICC = 0,97) and good reproducibility between the first test and one week later (ICC = 0,79). All ICC tests had p<0,001.
There was excellent level of reproducibility within one week to average and peak parameters on the untreated group. There was no statistically significant difference between Day 2 and Day 1 or Week 1 and Day 1 for the average and peak parameters on the untreated group. There was significant reduction on Day 2 and Week 1 to average and peak parameters compared to Day 1 on the treated group. There was reduction to average and peak parameters on the treated group compared to the untreated group during the same period. We conclude that it is possible to perform monocular therapeutic test with bimatoprost 0.01% in a week considering that the contralateral eye untreated group did not change throughout the study period and there was intraocular pressure reduction on the treated group compared to baseline and untreated group
This PDF is available to Subscribers Only